We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Synthorx Inc | NASDAQ:THOR | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 67.99 | 67.00 | 67.99 | 0 | 01:00:00 |
From Jul 2019 to Jul 2024
| Jefferies London Healthcare Conference Date: November 20, 2019 Time: 9:20 a.m. BT (4:20 a.m. ET)Location: London, UKStifel 2019 Healthcare Conference Date: November 20, 2019 Time: 10:20 a.m. ET Location: New York, NYEvercore ISI 2nd Annual HealthCONx Conference Date: December 3, 2019 Time: 2:20 p.m. ET Location: Boston, MA |
Live webcasts of the company’s presentations will be available at Synthorx’ investor relations website. An archived replay will be available for 60 days following the presentation.
To receive Synthorx’ press releases and other investor information, please visit the Investor Relations page of the Company’s website and register for email alerts.
About SynthorxSynthorx, Inc. is a clinical-stage biotechnology company focused on prolonging and improving the lives of people with cancer and autoimmune disorders. Synthorx’ proprietary, first-of-its-kind Expanded Genetic Alphabet platform technology expands the genetic code by adding a new DNA base pair and is designed to create optimized biologics, referred to as Synthorins™. A Synthorin is a protein optimized through incorporation of novel amino acids encoded by the new DNA base pair that enables site-specific modifications, which enhance the pharmacological properties of these therapeutics. The company’s lead immuno-oncology (IO) product candidate, THOR-707, a variant of IL-2, is in development in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. The company was founded based on important discoveries by Dr. Floyd Romesberg and The Scripps Research Institute. Synthorx is headquartered in La Jolla, Calif. For more information, visit www.synthorx.com.
Investor Relations Contacts: Enoch Kariuki, Pharm.D.Synthorx, Inc.ekariuki@synthorx.com 858-750-4750
Christina TartagliaStern IR, Inc.christina.tartaglia@sternir.com212-362-1200
Media Relations Contact:Lauren FishCanale Communicationslauren@canalecomm.com619-849-5386
1 Year Synthorx Chart |
1 Month Synthorx Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
